7月16日,国家药品监督管理局(NMPA)药品审评中心(CDE)网站显示,百济神州的注射用塔拉妥单抗(tarlatamab)上市申报获受理。此前,该药物已被纳入优先审评程序,拟用于既往接受过至少二线治疗(包括含铂化疗)失败的广泛期小细胞肺癌(ES-SCLC)成人患者的治疗。塔拉妥单抗作为同类首创(First-in-class)的DLL3/CD3双特异性抗体,或将为小细胞肺癌(SCLC)患者的后线...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.